Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase NA 1Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Multiple Myeloma 2Uterine Cervical Neoplasms 1Solid Tumor, Adult 1Recurrence 1Obesity 1Nutrition Disorders 1Neoplasms 1Motor Activity 1Hypertension 1Diabetes Mellitus 1Depression 1Cardiovascular Diseases 1Anus Neoplasms 1

Interventions

Dexamethasone 33Cyclophosphamide 29venetoclax 18fludarabine 18Lenalidomide 16Bortezomib 16Cytarabine 13pembrolizumab 12Calcium Dobesilate 12Carboplatin 11fludarabine phosphate 10Rituximab 10pomalidomide 9Gemcitabine 9Nivolumab 8Azacitidine 7daratumumab 6carfilzomib 6blinatumomab 6Decitabine 6Bendamustine Hydrochloride 6selinexor 5obinutuzumab 5ibrutinib 5Vincristine 5Temozolomide 5Methotrexate 5Etoposide 5Cisplatin 5tafasitamab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Recurrence × Therapeutics × Clear all
NCT07542717 2026-04-21

ASCERV Study: MRG003 Combined With QL1706 in Recurrent or Metastatic Cervical Cancer

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 1/2 Not yet recruiting
41 enrolled
Gynecologic

Uterine Cervical Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡